

ASX Release
29 September 2023

**ASX code: PIQ** 

# **Proteomics International Webinar and Q&A**

Proteomics International Laboratories Ltd (Proteomics International; the Company; ASX: PIQ) is pleased to invite shareholders, investors and interested parties to an online update on the recent announcement regarding the PromarkerD US Reimbursement Price and the Australian Regulatory Decision, hosted by MD, Dr Richard Lipscombe.

### The webinar will be held on Tuesday 3<sup>rd</sup> October 2023 at 12:00pm AEDT / 11:00am AEST / 9:00am AWST

For the Q&A session, investors are invited to send questions for the webinar prior to 5:00pm AEDT Monday 2<sup>nd</sup> October 2023 to: *dirk@candouradvisory.com.au* 

Register for the webinar at the link below:

## https://ccmediaframe.com/?id=vnANCI38

After registering, you will receive a confirmation email containing information about joining the webinar. A recording will be available at the above link shortly after the conclusion of the live session.

Authorised by the Board of Proteomics International Laboratories Ltd (ASX: PIQ).

**ENDS** 

# About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

## For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd

T: +61 8 9389 1992

E: enquiries@proteomicsinternational.com

Dirk van Dissel Kyle Moss

Investor Relations & Corporate Advisor
Candour Advisory
T: +61 408 326 367
Corporate Advisor
Euroz Hartleys
T: +61 8 9488 1400

E: dirk@candouradvisory.com.au E: kmoss@eurozhartleys.com

**Proteomics International Laboratories Ltd** 

ABN 78 169 979 971